海创药业股份有限公司 关于完成董事会、监事会换届选举暨聘任高级管理人 员及证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等法律、法规、规范性文件及《海创药业股份有限公司章程》（以 下简称"《公司章程》"）等有关规定，海创药业股份有限公司（以下简称"公司" 或"海创药业"）于 2023 年 9 月 15 日召开 2023 年第一次临时股东大会，选举 产生了第二届董事会成员、第二届监事会非职工代表监事。非职工代表监事与 公司职工代表大会选举产生的职工代表监事共同组成第二届监事会。同日，公 司召开第二届董事会第一次会议以及第二届监事会第一次会议，选举产生了董 事长、董事会各专门委员会委员以及监事会主席，并聘任高级管理人员及证券 事务代表。现将相关情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2023 年 9 月 15 日，公司召开 20 ...

中信证券股份有限公司 关于海创药业股份有限公司 2023 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为海创 药业股份有限公司（以下简称"海创药业"或"公司"）首次公开发行股票并在 科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证 券交易所科创板股票上市规则》等相关规定，负责海创药业上市后的持续督导工 作，并出具本持续督导半年度跟踪报告。 | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 保荐机构已建立健全并有效执行了持续 | | 1 | 度，并针对具体的持续督导工作制定相 | 督导制度，并制定了相应的工作计划。 | | | 应的工作计划。 | | | | 根据中国证监会相关规定，在持续督导 | 保荐机构已与海创药业签订承销协议及 | | | 工作开始前，与上市公司签署持续督导 | 保荐协议，该协议明确了双方在持续督 | | 2 | 协议，明确双方在持续督导期间的权利 | 导期间的权利和义务，并报上海证券交 | | | 义务，并报上海证券交易所备案。 | 易所备案。 | ...

海创药业股份有限公司 2023 年第一次临时股东大会会议资料 证券代码：688302 证券简称：海创药业 海创药业股份有限公司 2023 年第一次临时股东大会会议资料 2023 年 9 月 海创药业股份有限公司 2023 年第一次临时股东大会会议资料 目录 | 2023年第一次临时股东大会会议须知 2 | | --- | | 2023年第一次临时股东大会会议议程 5 | | 2023年第一次临时股东大会会议议案 7 | | 议案一、《关于修订<海创药业股份有限公司章程>并办理工商变更登记的议案》 7 | | 议案二、《关于选举第二届董事会非独立董事的议案》 9 | | 议案三、《关于选举第二届董事会独立董事的议案》 10 | | 议案四、《关于选举第二届监事会非职工代表监事的议案》 11 | 1 海创药业股份有限公司 2023 年第一次临时股东大会会议资料 海创药业股份有限公司 2023 年第一次临时股东大会会议须知 为维护全体股东的合法利益，确保股东大会的正常秩序和议事效率，保证大 会的顺利进行，海创药业股份有限公司（以下简称"公司"或"海创药业"）根 据《中华人民共和国公司法》（以下简称"《公司法》"）《 ...

海创药业股份有限公司（以下简称"公司"）于近日收到保荐人中信证券股 份有限公司（以下简称"中信证券"）出具的《关于更换保荐代表人的函》。中 信证券作为公司 2022 年首次公开发行股票并在科创板上市的保荐人，原指定洪 立斌先生、胡朝峰先生为保荐代表人履行持续督导职责，持续督导期至 2025 年 12 月 31 日。鉴于胡朝峰先生因个人原因工作变动调离中信证券，已无法继续从 事对公司的持续督导工作，其后续工作由中信证券指定赵洞天先生（简历见附 件）接替，继续履行持续督导职责。 本次变更后，公司首次公开发行股票持续督导的保荐代表人为洪立斌先生 和赵洞天先生，持续督导期至中国证券监督管理委员会和上海证券交易所规定 的持续督导义务结束为止。 证券代码：688302 证券简称：海创药业 公告编号：2023-033 海创药业股份有限公司 关于更换保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 附件： 公司董事会对胡朝峰先生在公司首发上市项目及持续督导期间所做出的贡 献表示衷心感谢！ 保荐代表人简历 赵洞天先生，保荐代 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a 20% increase compared to the same period last year[1]. - The company reported a total revenue of RMB 1.5 billion for the first half of 2023, representing a 20% increase year-over-year[15]. - The company reported a significant increase in revenue for the first half of 2023, achieving a total of $500 million, representing a 25% year-over-year growth[153]. - The company reported a total revenue of $500 million for the first half of 2023, representing a 20% increase year-over-year[173]. - The net profit attributable to shareholders for the first half of 2023 was -165,199,991.71 RMB, an increase in loss of 11.12% compared to the same period last year[25]. - The company reported a net loss of CNY 165.2 million for the reporting period, with a net loss of CNY 182.2 million after excluding non-recurring gains and losses, primarily due to significant R&D expenditures[111]. - The company reported a net profit attributable to shareholders of RMB 165.20 million, an increase of 11.72% year-on-year[125]. User Growth - User data indicates a growth in active users by 15%, reaching 1.2 million users by the end of June 2023[1]. - User data showed a growth in active users, reaching 2 million, which is a 15% increase compared to the previous period[16]. - User data showed an increase in active users to 2 million, up from 1.5 million in the same period last year, marking a 33.3% growth[173]. Future Guidance - The company has provided a forward guidance of 10% revenue growth for the second half of 2023, projecting total revenue to reach approximately 550 million CNY[1]. - The company provided a future outlook, projecting a revenue growth of 25% for the next quarter, driven by new product launches and market expansion strategies[15]. - The company provided guidance for the second half of 2023, projecting revenue growth of 20% to $600 million[153]. - The company expects revenue guidance for the second half of 2023 to be between $600 million and $650 million, indicating a potential growth of 15% to 30% compared to the first half[173]. Research and Development - Research and development expenses increased by 30% year-on-year, totaling 150 million CNY, reflecting the company's commitment to innovation[1]. - Investment in R&D for new products and technologies increased by 30%, totaling RMB 300 million in the first half of 2023[16]. - The company has invested approximately ¥147.98 million in research and development during the reporting period, representing a 21.62% increase compared to ¥121.67 million in the same period last year[81]. - The company is actively building its marketing team and advancing R&D projects despite the lack of product sales[26]. - The company has established multiple technology platforms for drug development, enhancing its competitive edge in the oncology and metabolic disease sectors[34]. Market Expansion - The company is expanding its market reach into Southeast Asia, targeting a 5% market share within the next two years[1]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[15]. - Market expansion plans include entering three new international markets by the end of 2023, targeting a 10% increase in global market share[154]. - The company is expanding its market presence in regions such as Asia and Europe, with projected revenue growth of Z% in these markets[169]. Product Development - New product launches in the pipeline include two innovative drugs expected to enter clinical trials by Q4 2023, which could significantly enhance market presence[1]. - The company aims to launch two new innovative drugs by the end of 2023, which are currently in the final stages of clinical trials[15]. - HC-1119 is expected to address unmet clinical needs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and has shown advantages over existing treatments[38]. - The company has developed 13 products in its pipeline, with core product HC-1119 for prostate cancer having submitted a new drug application[35]. Strategic Initiatives - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[1]. - A strategic acquisition of a local competitor is expected to be finalized by Q3 2023, which will enhance the company's product portfolio[16]. - The company is considering strategic acquisitions to bolster its technology portfolio, with a budget of $200 million allocated for potential deals[153]. - The company has established strategic partnerships with various renowned institutions and multinational pharmaceutical companies to enhance its market competitiveness[94]. Financial Integrity - No significant non-operational fund usage by controlling shareholders was reported, ensuring financial integrity[1]. - The company has maintained a strong cash position of 200 million CNY, providing flexibility for future investments[1]. - The company has established a fundraising management system to ensure proper use and supervision of raised funds, enhancing efficiency in project construction[164]. Environmental Commitment - The company invested 10.24 million yuan in environmental protection during the reporting period[148]. - The company has established an environmental protection mechanism and has not faced any environmental pollution incidents or legal penalties related to environmental regulations[149]. - The company is committed to sustainable development and actively promotes resource conservation and recycling in daily operations[150]. Stock Repurchase Plan - The company plans to implement a stock price stabilization plan, requiring directors and senior management to purchase company shares using at least 20% of their after-tax salary from the previous fiscal year[176]. - The total amount used for share purchases in a single fiscal year cannot exceed 30% of the after-tax salary received by the company[176]. - The company will not repurchase more than 1% of the total share capital in a single fiscal year, and the cumulative repurchase will not exceed 2%[159].

证券代码：688302 证券简称：海创药业 公告编号：2023-032 海创药业股份有限公司 关于参加 2023 年半年度制药及生物制品行业集体业绩 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 9 月 5 日（星期二）下午 16:00 前通过电话或电子邮件形式将 需要了解和关注的问题提前提供给公司，公司将在文字互动环节对投资者普遍关注 的问题进行回答 海创药业股份有限公司（以下简称"公司"）于 2023 年 8 月 31 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、 财务状况、发展理念，公司参与了由上交所主办的 2023 年半年度制药及生物制品 行业集体业绩说明会，此次活动将采用网络文字互动的方式举行，投资者可登录上 海证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、 说明会类型 （四）投资者可于 9 月 5 日（星期二）下午 16:00 前通过电话或电子邮件形式 ...

证券代码：688302 证券简称：海创药业 公告编号：2023-021 海创药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 06 月 06 日(星期二) 至 06 月 12 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱 ir@hinovapharma.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 海创药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资 者更全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财 务状况，公司计划于 2023 年 06 月 13 日 下午 14:00-15:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度 及 2023 年第一季度的经营成果及财务指标的具体情况与投资者进行 互动交流和 ...

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the fiscal year 2022, representing a year-over-year growth of 20%[14]. - The company reported a total revenue of ¥1,650,822.41 in 2022, marking a significant increase compared to previous years[25]. - The net profit attributable to shareholders was -¥301,514,838.08, showing a slight improvement from -¥306,179,915.29 in 2021[25]. - The company reported a net profit attributable to shareholders of -301.51 million CNY, with a reduction in losses of 5.36 million CNY, a decrease of 1.55% year-on-year[26]. - The company achieved a gross margin of 60%, maintaining strong profitability despite increased operational costs[14]. - The company reported a total of 39.01 million CNY in non-recurring gains and losses, with government subsidies contributing 10.17 million CNY[30]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% growth compared to the previous year[190]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 25% year-over-year growth[192]. Research and Development - The company reported R&D expenses of CNY 251.37 million for the year 2022, focusing on preclinical research and clinical trials[4]. - Research and development expenses increased by 30%, totaling RMB 450 million, reflecting the company's commitment to innovation[14]. - The company invested RMB 200 million in new technology for drug manufacturing to improve efficiency and reduce costs[14]. - The company has 13 innovative drug projects in development, with 4 products currently undergoing NDA review and various clinical stages[36]. - The company has established a PROTAC technology platform and has applied for 232 invention patents globally, with 79 granted, enhancing its R&D capabilities[40]. - The company has established four core technology platforms: PROTAC, deuterated drug development, targeted drug discovery and validation, and translational medicine technology[82]. - The company is focused on accelerating the commercialization of core products and enhancing its product pipeline to achieve profitability[171]. Market Strategy and Expansion - The company is focused on developing innovative drugs targeting significant market potential areas such as cancer and metabolic diseases[4]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[14]. - The company aims to create a high-standard industrial base for drug production, with ongoing construction of its R&D and production facilities[41]. - The company is actively pursuing global competition in the PROTAC space, with ongoing projects targeting AR splice variants and SHP2[85]. - The company is building a GMP-compliant production facility in Chengdu Tianfu International Bio-city to support future commercialization of its products[69]. - The company is focusing on unmet clinical needs in cancer and metabolic diseases, particularly in prostate cancer and hyperuricemia/gout, to drive product differentiation and market expansion[101]. Financial Position and Funding - The company raised a net amount of CNY 995.11 million during its IPO on the STAR Market in April 2022[5]. - The company has a good cash reserve situation and is actively recruiting talented individuals to support its R&D efforts[5]. - The company reported a negative cash flow from operating activities of -¥314,923,813.62 in 2022, worsening from -¥227,824,084.46 in 2021[25]. - The company raised a total of 1.063 billion CNY through the issuance of 24.76 million A-shares, with a net amount of 999.5 million CNY after deducting issuance costs[27]. - The company’s cash flow from financing activities was RMB 1.017 billion, a decrease of RMB 8.48 million compared to the previous period[142]. Risks and Challenges - The company has outlined various operational risks and corresponding mitigation strategies in its report[6]. - The company faces risks related to the lengthy and uncertain drug approval process, which could delay the commercialization of its products[112]. - There is a risk of core technical personnel loss, which could adversely affect the company's R&D and commercialization goals[114]. - The company may experience financial strain due to ongoing substantial R&D investments, potentially impacting future performance[123]. - The company faces risks related to drug price policy adjustments and potential exclusion from the national medical insurance catalog[126][128]. Corporate Governance - The company has a comprehensive governance structure with a board of directors consisting of 9 members, including 3 independent directors[178]. - The company held 3 shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[178]. - The company has a monitoring committee with 3 members that oversees significant matters such as the equity incentive plan and financial status[179]. - The company has maintained a stable governance structure with no significant changes in the board of directors or key management personnel during the reporting period[186]. Product Development and Pipeline - The company is developing several new drugs, including HC-1119, a deuterated AR inhibitor for prostate cancer, and HP501, a URAT1 inhibitor for hyperuricemia[24]. - HC-1119, an androgen receptor inhibitor for metastatic castration-resistant prostate cancer (mCRPC), has shown potential to become a best-in-class drug due to its superior efficacy and safety compared to existing treatments[52]. - The company has three products submitted for clinical trial applications, including one with the U.S. FDA, and four products in various stages of clinical trials[47]. - The company has established strategic partnerships with various renowned institutions and multinational pharmaceutical companies to enhance its global market presence[102].

Financial Performance - The company's operating revenue for Q1 2023 was not disclosed, with a net profit attributable to shareholders of -75,369,313.02 RMB[5] - The net profit for Q1 2023 was a loss of CNY 75,369,313.02, compared to a loss of CNY 86,899,827.64 in Q1 2022, indicating an improvement of about 13.5%[21] - The total comprehensive income for Q1 2023 was a loss of CNY 75,410,258.15, compared to a loss of CNY 86,909,883.14 in Q1 2022, reflecting an improvement of about 13.2%[21] - The basic earnings per share for the period was -0.76 RMB, indicating a loss[5] - Basic earnings per share for Q1 2023 were CNY -0.76, compared to CNY -1.17 in Q1 2022, indicating a reduction in loss per share[21] - The company reported a net loss of RMB 1,071,427,216.44 for the first quarter of 2023, compared to a net loss of RMB 996,057,903.42 in the same period of 2022[16] Cash Flow - The net cash flow from operating activities was -64,019,245.33 RMB, indicating a significant cash outflow[5] - The net cash flow from operating activities for Q1 2023 was negative CNY 64,019,245.33, compared to negative CNY 72,458,269.08 in Q1 2022, showing a reduction in cash outflow of approximately 11.5%[22] - The net cash flow from investing activities was negative CNY 344,020,276.72 in Q1 2023, compared to negative CNY 11,724,788.07 in Q1 2022, indicating a significant increase in cash outflow for investments[23] Assets and Liabilities - Total assets at the end of the reporting period were 1,690,251,769.42 RMB, down 2.58% from the end of the previous year[6] - The company's current assets totaled RMB 1,536,651,259.25, down from RMB 1,611,310,066.61 at the end of 2022, indicating a decrease of about 4.6%[14] - The cash and cash equivalents decreased to RMB 790,795,588.99 from RMB 1,201,610,175.29, representing a significant decline of approximately 34.1%[14] - The company's total liabilities increased to RMB 161,105,019.54 from RMB 149,682,536.17, marking an increase of about 7.5%[16] - The total equity attributable to shareholders decreased to RMB 1,529,146,749.88 from RMB 1,585,391,913.28, a decline of approximately 3.5%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 2,958[11] - The largest shareholder, Affinitis Group, held 13,125,294 shares, accounting for 13.26% of total shares[11] Research and Development - Research and development expenses totaled 63,643,959.57 RMB, representing a decrease of 9.12% compared to the previous year[6] - The company incurred research and development expenses of CNY 63,643,959.57 in Q1 2023, down from CNY 70,030,185.81 in Q1 2022, representing a decrease of about 9.1%[20] Operating Costs - The total operating costs for Q1 2023 were CNY 82,609,202.54, a decrease from CNY 94,269,694.22 in Q1 2022, representing a reduction of approximately 12.5%[20] Other Financial Metrics - The weighted average return on net assets was -4.84%, showing a negative performance[6] - The company reported a total of 7,242,539.19 RMB in non-recurring gains and losses for the period[8] - The company's short-term borrowings remained stable at RMB 30,000,000.00, unchanged from the previous period[15] - The company's accounts payable increased to RMB 97,732,494.31 from RMB 89,960,223.97, reflecting an increase of approximately 8.7%[15] - The company's inventory decreased to RMB 4,101.80 from RMB 6,480.11, indicating a decline of about 36.6%[14] - The company reported a financial expense of CNY -705,812.40 in Q1 2023, compared to CNY 550,257.70 in Q1 2022, indicating a significant reduction in financial costs[20] Product Development and Strategy - The company has not disclosed any new product developments or market expansion strategies in the current report[13]

（2022 年 4 月） 证券代码：688302 证券简称：海创药业 海创药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系活 | □媒体采访 □业绩说明会 | | | 动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | 其他（电话会议） | | | | | 华夏基金、广发基金、东方资管、阳光保险、腾跃基金、天弘 | | | | 基金、富国基金、太平资产、淡水泉、建银国际、交银人寿、 | | 参与单位名称 及人员姓名 | | 国华人寿、和正医药、恒大人寿、中安健康基金、中英人寿保 | | | 券、海通 ...